Urology

Discover a study that reveals a targetable CA125+ cell state in rare bladder cancer subtypes using single-cell RNA sequencing.

Learn how EGF and UMOD levels may predict diabetic kidney disease progression, offering new tools for clinical risk assessment.

Non-muscle invasive bladder cancer, representing roughly 75% of cases, remains confined to the bladder lining and submucosa, often recurring but rarely advancing.

Patients treated on the entire prostate or surgical bed had better DMFS compared to those treated only on the relapse site.

Results showed that US overestimated bladder volumes compared to CBCT, with an average deviation of 60.75 ml.

Profiling urine tumour DNA at baseline and after 3 months of treatment could identify whether patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer might not benefit from systemic immunotherapy.

These insights are particularly relevant in minimally invasive surgery, where precision and confidence are vital.

The GETSBI study is not only crucial for this specific patient group but also holds broader implications for research in rare, chronic conditions.